Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids
Saved in:
Barocas, J.A., et al., Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids. International Journal of Drug Policy, vol. 72, 2019, p. 160-168.
Ref.
576285
Location:
SIIS Archivo (R.1114)
Palabras clave:
Drogodependencias, Opiáceos, Buprenorfina
Drogodependencias, Opiáceos, Buprenorfina
Similar Items: Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids
- EFFECTS OF BUPRENORPHINE AND NALOXONE IN MORPHINE-STABILIZED OPIOID ADDICTS
- The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers
- PAIN AND CONTINUED OPIOID USE IN INDIVIDUALS RECEIVING BUPRENORPHINE-NALOXONE FOR OPIOID DETOXIFICATION: SECONDARY ANALYSES FROM THE CLINICAL TRIALS NETWORK
- COST ANALYSIS OF CLINIC AND OFFICE-BASED TREATMENT OF OPIOID DEPENDENCE: RESULTS WITH METHADONE AND BUPRENORPHINE IN CLINICALLY STABLE PATIENTS
- Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone
- BUPRENORPHINE: A CONTROLLED CLINICAL TRIAL IN THE TREATMENT OF OPIOID DEPENDENCE